Ark. judge fines J&J and unit $1.2B over Risperdal marketing

04/11/2012 | CNNMoney

An Arkansas judge said Johnson & Johnson and unit Janssen Pharmaceuticals must pay $1.2 billion for violating the state's False Claims and Deceptive Trade Practices acts in regard to marketing antipsychotic Risperdal. The penalty signals that big drugmakers "cannot lie to the FDA, patients and doctors in order to defraud Arkansas taxpayers of our Medicaid dollars," Arkansas Attorney General Dustin McDaniel said. A spokeswoman for Janssen said evidence showed the firms acted legally, and they will appeal.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC